Barinthus Biotherapeutics/$BRNS
BRNS jumps after announcing all-stock merger with Clywedog Therapeutics expected to close in H1 2026.
2 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Barinthus Biotherapeutics
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
Ticker
$BRNS
Sector
Primary listing
Employees
14
Headquarters
Website
BRNS Metrics
BasicAdvanced
$22M
-
-$1.64
-0.62
-
Price and volume
Market cap
$22M
Beta
-0.62
52-week high
$2.92
52-week low
$0.51
Average daily volume
46K
Financial strength
Current ratio
7.765
Quick ratio
7.163
Long term debt to equity
12.462
Total debt to equity
15.185
Interest coverage (TTM)
-1,138.59%
Profitability
EBITDA (TTM)
-55.223
Effective tax rate (TTM)
0.26%
Management effectiveness
Return on assets (TTM)
-28.08%
Return on equity (TTM)
-65.02%
Valuation
Price to book
0.3
Price to tangible book (TTM)
0.37
Price to free cash flow (TTM)
-0.456
Free cash flow yield (TTM)
-219.37%
Free cash flow per share (TTM)
-1.185
Growth
Earnings per share change (TTM)
5.66%
3-year earnings per share growth (CAGR)
127.11%
What the Analysts think about BRNS
Analyst ratings (Buy, Hold, Sell) for Barinthus Biotherapeutics stock.
BRNS Financial Performance
Revenues and expenses
BRNS Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Barinthus Biotherapeutics stock?
Barinthus Biotherapeutics (BRNS) has a market cap of $22M as of April 02, 2026.
What is the P/E ratio for Barinthus Biotherapeutics stock?
The price to earnings (P/E) ratio for Barinthus Biotherapeutics (BRNS) stock is 0 as of April 02, 2026.
Does Barinthus Biotherapeutics stock pay dividends?
No, Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders as of April 02, 2026.
When is the next Barinthus Biotherapeutics dividend payment date?
Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders.
What is the beta indicator for Barinthus Biotherapeutics?
Barinthus Biotherapeutics (BRNS) has a beta rating of -0.62. This means that it has an inverse relation to market volatility.